Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers.

Dobrotkova V, Chlapek P, Jezova M, Adamkova K, Mazanek P, Sterba J, Veselska R.

PLoS One. 2019 Jun 12;14(6):e0218269. doi: 10.1371/journal.pone.0218269. eCollection 2019.

2.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

3.

Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy.

Dobrotkova V, Chlapek P, Mazanek P, Sterba J, Veselska R.

BMC Cancer. 2018 Nov 1;18(1):1059. doi: 10.1186/s12885-018-4966-5. Review.

4.

Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids.

Chlapek P, Slavikova V, Mazanek P, Sterba J, Veselska R.

Int J Mol Sci. 2018 Jan 3;19(1). pii: E132. doi: 10.3390/ijms19010132. Review.

5.

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J.

Pediatr Hematol Oncol. 2017 Aug;34(5):308-319. doi: 10.1080/08880018.2017.1373314. Epub 2017 Nov 17.

PMID:
29148865
6.

Future paradigms for precision oncology.

Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, Carmassi P, Rietman E, Slaby O, Mazanek P, Mudry P, Kovacs G, Kiss C, Norga K, Konstantinov D, André N, Slavc I, van Den Berg H, Kolenova A, Kren L, Tuma J, Skotakova J, Sterba J.

Oncotarget. 2016 Jul 19;7(29):46813-46831. doi: 10.18632/oncotarget.9488. Review.

7.

[Eye manifestation of extrarenal malignant rhabdoid tumour].

Prívarová E, Griščíková L, Lokaj M, Vokurková J, Mazánek P, Autrata R.

Cesk Slov Oftalmol. 2014 Apr;70(2):62-5. Czech.

PMID:
25030315
8.

Extension of microRNA expression pattern associated with high-risk neuroblastoma.

Bienertova-Vasku J, Mazanek P, Hezova R, Curdova A, Nekvindova J, Kren L, Sterba J, Slaby O.

Tumour Biol. 2013 Aug;34(4):2315-9. doi: 10.1007/s13277-013-0777-0. Epub 2013 Jun 20.

PMID:
23784455
9.

Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.

Zapletalova D, André N, Deak L, Kyr M, Bajciova V, Mudry P, Dubska L, Demlova R, Pavelka Z, Zitterbart K, Skotakova J, Husek K, Martincekova A, Mazanek P, Kepak T, Doubek M, Kutnikova L, Valik D, Sterba J.

Oncology. 2012;82(5):249-60. doi: 10.1159/000336483. Epub 2012 Apr 24.

PMID:
22538363
10.

Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination.

Mudry P, Vavrina M, Mazanek P, Machalova M, Litzman J, Sterba J.

Arch Dis Child. 2011 May;96(5):476-7. doi: 10.1136/adc.2010.198184. Epub 2011 Jan 10.

PMID:
21220258
11.

[Changes of neurocognitive functions as result of cancer treatment in children and adolescents].

Vlcková I, Pavelková K, Kepák T, Pilát M, Bajciová V, Mazánek P, Sterba J, Jelínek M.

Klin Onkol. 2008;21(5):294-302. Review. Czech.

PMID:
19202961
12.

Efficacy of pregabalin in neuropathic pain in paediatric oncological patients.

Vondracek P, Oslejskova H, Kepak T, Mazanek P, Sterba J, Rysava M, Gal P.

Eur J Paediatr Neurol. 2009 Jul;13(4):332-6. doi: 10.1016/j.ejpn.2008.06.011. Epub 2008 Sep 6.

PMID:
18774740
13.

Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.

Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R, Jagannathan J, Cnaan A, Maris JM, Hogarty MD.

Oncogene. 2008 Feb 28;27(10):1478-88. Epub 2007 Aug 27.

PMID:
17724465
14.

Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study.

Sterba J, Valik D, Mudry P, Kepak T, Pavelka Z, Bajciova V, Zitterbart K, Kadlecova V, Mazanek P.

Onkologie. 2006 Jul;29(7):308-13. Epub 2006 Jul 3.

PMID:
16874014
15.

Mutations in PIK3CA are infrequent in neuroblastoma.

Dam V, Morgan BT, Mazanek P, Hogarty MD.

BMC Cancer. 2006 Jul 5;6:177.

16.

[Management of couples following prenatal diagnosis of fetal abnormalities].

Langer M, Ringler M, Mazanek P.

Geburtshilfe Frauenheilkd. 1987 Mar;47(3):186-9. German.

PMID:
3582925

Supplemental Content

Loading ...
Support Center